Glenmark Pharmaceuticals’ arm enters into agreement for Aumolertinib

17 Dec 2025 Evaluate

Glenmark Pharmaceuticals’ wholly owned subsidiary -- Glenmark Specialty S.A. (GSSA) has entered into an exclusive license, collaboration and distribution agreement with Jiangsu Hansoh Pharmaceutical Group Co (Hansoh Pharma) for Aumolertinib, a third-generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) for the treatment of non-small cell lung cancer (NSCLC).

Under the terms of the agreement, Glenmark receives exclusive rights to develop and commercialize Aumolertinib across its licensed territories: Middle East and Africa, Southeast & South Asia, Australia, New Zealand, Russia/CIS and a few selected Caribbean countries covered by the agreement. Hansoh Pharma will receive an upfront payment of low double-digit million USD, followed by potential regulatory and commercial milestone payments possibly cumulating to over $1 billion, in addition to tiered royalties on net sales in the licensed territories.

Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.

Glenmark Pharma Share Price

1952.00 -14.05 (-0.71%)
17-Dec-2025 12:57 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1785.70
Dr. Reddys Lab 1276.50
Cipla 1494.40
Zydus Lifesciences 918.00
Lupin 2110.00
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×